HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Novel treatments, deeper understanding of glioblastoma biology lead to ‘turning point’
• Science is an iterative process Amanda I. Phipps, MPH, PhD
• Physicians’ political beliefs may impact patient care
• Cancer epidemiology today: Not strengthening the value proposition Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA grants accelerated approval to Rubraca for advanced, BRCA–positive ovarian cancer
• FDA grants orphan drug designation to ES-3000 for AML
• FDA grants priority review to Keytruda for Hodgkin lymphoma
• OIG publishes safe harbor for the provision of local transportation services
• BRCA1 mutations linked to increased risk for serous, serous-like endometrial carcinoma
• Breast cancer risk after atypical ductal hyperplasia may be overstated
• Dasatinib activity varies by sarcoma subtype
• Educational intervention reduces fear of cancer recurrence in melanoma survivors
• Medicare beneficiaries without supplemental insurance hit hardest by cancer costs
• Novel liquid biopsy assay rapidly identifies mutations in NSCLC
• Prediagnostic wine consumption may slightly improve colorectal cancer survival outcomes
• Single-agent venetoclax shows promise in relapsed, refractory AML
• Tumor resection of at least 90% improves EFS in pediatric neuroblastoma
• Abemaciclib reduces Ki67 expression in certain postmenopausal women with breast cancer
• AG-348 safe, tolerable in congenital hemolytic anemia
• Aromatase inhibitors associated with poorer endothelial function in postmenopausal women
• ASH recognizes three Choosing Wisely Champions
• Beat AML trial designed to match ‘right patient with the right drug’
• Buparlisib prolongs PFS in certain postmenopausal women with advanced breast cancer
• Certain menopausal symptoms associated with nonadherence to breast cancer therapy
• DCIS associated with high rates of positive margins at lumpectomy
• Estrogen deprivation does not significantly improve pathologic complete response in hormone receptor–positive breast cancer
• Estrogen deprivation does not significantly improve pathologic complete response in hormone receptor–positive breast cancer
• Gene transfer sustains stable Factor IX levels in hemophilia B
• Guadecitabine shows promise in high-risk myelodysplastic syndrome, CMML
• IBM Watson for Oncology platform highly concordant with physician recommendations
• Ibrutinib yields durable responses in chronic GVHD
• Induction regimen associated with durable response, low toxicity in mantle cell lymphoma
• Lenalidomide maintenance prolongs PFS in high-risk CLL
• Luspatercept increases hemoglobin, decreases transfusion burden in beta-thalassemia
• Matching sibling peripheral blood–based grafts improve outcomes for thalassemia major
• Pacritinib more effective than best available therapy for myelofibrosis with low platelets
• Patients with CML with stable molecular response may reduce TKI dose by half
• Peripherally inserted central catheters increase VTE risk among children
• Pertuzumab improves PFS for HER-2–positive breast cancer
• Reduced-intensity delayed intensification does not benefit standard-risk children with ALL
• Researchers seek clearer guidelines for red blood cell transfusions
• Rituximab after autologous HSCT improves EFS in mantle cell lymphoma
• Some patients with early-stage breast cancer may be able to avoid axillary lymph node dissection
• Symptomatic venous thrombotic events complicate outcomes in pediatric oncology patients
• Tandem transplant, RVD consolidation after upfront HSCT do not improve outcomes in myeloma
• TKI cessation feasible for patients with CML in deep molecular remission
• Should immunotherapy be the standard of care for patients with glioblastoma?